

Performance In Delivering - Q4: 2017/2018 (1st April 2017 - 31st March 2018)

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Target number of patients agreed?	Target minimum number of patients	Target maximum number of patients	Date Agreed to recruit target number of patients	Number of patients recruited by agreed date	Total number of study participants recruited	Closed to Recruitment date	Reason for Closure
16/LO/1001	199167	A randomized, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to center-involved diabetic macular edema (DME)	Agreed	2	2	30/09/2017	3	3	22/06/2017	End of Recruitment
15/EM/0437	184390	Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD)	Agreed	6	6	09/06/2017	3	3	09/06/2017	End of Recruitment
17/SC/0022	215467	Panorama: A phase 3 double-masked randomised study of the efficacy and safety of intravitreal aflibercept injection in patients with moderately severe to severe nonproliferative diabetic retinopathy	Agreed	3	3	30/09/2017	1	1	07/08/2017	End of Recruitment
15/EM/0552	189887	CIRCLE: A randomised, sham-controlled, double-masked, multi-centre study to evaluate the effect of ocriplasmin 0.125mg in subjects with non-proliferative diabetic retinopathy (NPDR)	Agreed	3	3	31/07/2017	1	3	07/12/2017	End of Recruitment
16/LO/2128	216431	PANORAMA: Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)	Agreed	22	22	28/02/2019	9	9	09/11/2017	End of Recruitment - study closed early